26 May 2026

strategyland.uk

Smith & Nephew PLC (SN)

Rank #21 of 100 - Healthcare - UK Equities

Home/Stocks/Healthcare

Smith & Nephew PLC

SN.L·Healthcare·Market Cap £9.8b

Rank #21 of 100

Data from Excel Model · 100 Stocks Analysed

£11.41

-7.55% YTD

Target: £14.16(+24.0%)

52W: £10.50 - £14.41

Score Analysis

Smith & Nephew PLC is ranked #21 out of 100 UK stocks. Lower factor scores indicate better performance in that category.

Factor Breakdown

47/100

Average Score

Liquidity

Excellent8/100

Valuation

Good39/100

Profitability

Fair52/100

Solvency

Good39/100

Asset Efficiency

Weak87/100

Mkt Trading

Fair55/100

Technical

Fair52/100

1. Valuation

Score: 39/100

Is SN undervalued compared to its peers and fair value metrics?

1/5

valuation criteria met

✗

FY26e P/E Ratio

13.4xRank 42/100

✓

FY27e P/E Ratio

11.9xRank 38/100

✗

Price-to-Book

2.68xRank 54/100

✗

Price-to-Tangible Book

10.92xRank 60/100

✗

EV/EBITDA

10.3xRank 50/100

Key Valuation Metrics

Current P/E

21.4x

Price-to-Earnings

FY26e P/E

13.4x

Forward estimate

FY27e P/E

11.9x

Forward estimate

P/B Ratio

2.68x

Price-to-Book

P/TBV

10.92x

Price-to-Tangible Book

EV/EBITDA

10.3x

Enterprise Value

FY26e EV/EBITDA

9.0x

Forward estimate

FY27e EV/EBITDA

9.0x

Forward estimate

Analyst Consensus Target

Current Price

£11.41

Consensus Target

£14.16

Potential

+24.0%

Target

Bloomberg Median Target: £14.00

2. Profitability

Score: 52/100

How profitable is SN relative to its peers?

0/6

profitability criteria met

✗

TTM Profit Margin

10.1%Rank 43/100

–

Current ROE

11.8%

–

Current ROA

N/A

✗

FY26e EPS

1.27Rank 48/100

–

TTM EPS

1.19

–

Net Income Growth

N/A

Profit Margin

10.1%

ROE

11.8%

FY27e ROE

17.4%

ROA

N/A

Earnings Per Share

3. Financial Health

Score: 39/100

How strong is SN's balance sheet and financial position?

0/4

solvency criteria met

–

Debt-to-Equity

62.9%

–

Interest Coverage

N/A

✗

Debt/EBITDA

Rank 55Rank 55/100

–

Altman Z-Score

3.54

Key Health Metrics

Quick Ratio

1.25

Healthy

Cash Ratio

2.57

Debt/Equity

63%

FCF Margin

1.0%

Altman Z-Score

3.54

Safe Zone

01.812.995+

4. Asset Efficiency

Score: 87/100

How efficiently does SN deploy its assets and intellectual capital?

1/2

asset efficiency criteria met

–

Intangible/Asset

Intangible assets as a proportion of total assets — lower indicates more tangible, capital-efficient operations

N/A

✓

R&D/Sales

Research & development spend relative to revenue — balanced R&D investment signals sustainable growth

Rank 4/100

Overall Asset Efficiency Rank

Rank within sector peers#87/100

Best (1)Worst (100)

What This Measures

Intangible/Asset — a lower ratio suggests the company's value is backed by tangible assets rather than goodwill or intangibles, reducing balance sheet risk.

R&D/Sales — captures the proportion of revenue reinvested into research and development, indicating innovation intensity and future growth investment.